TherapeuticsMD (NASDAQ:TXMD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Friday.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

A number of other research analysts have also recently issued reports on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 target price on shares of TherapeuticsMD in a research note on Sunday, January 7th. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research note on Friday, December 29th. Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Wednesday, December 20th. Finally, Deutsche Bank set a $9.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Wednesday, December 20th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. TherapeuticsMD has a consensus rating of “Buy” and a consensus target price of $14.50.

TherapeuticsMD (NASDAQ TXMD) opened at $6.15 on Friday. TherapeuticsMD has a one year low of $3.50 and a one year high of $8.30. The stock has a market cap of $1,330.00, a P/E ratio of -15.77 and a beta of 1.06.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The company had revenue of $4.42 million during the quarter, compared to analysts’ expectations of $5.36 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. TherapeuticsMD’s quarterly revenue was down 19.7% compared to the same quarter last year. equities analysts expect that TherapeuticsMD will post -0.37 earnings per share for the current fiscal year.

In related news, Director Tommy G. Thompson acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was purchased at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the transaction, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 23.92% of the company’s stock.

A number of hedge funds have recently bought and sold shares of TXMD. Amalgamated Bank raised its position in TherapeuticsMD by 7.2% in the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after purchasing an additional 1,322 shares during the last quarter. Principal Financial Group Inc. raised its position in TherapeuticsMD by 3.9% in the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in TherapeuticsMD in the 2nd quarter worth approximately $157,000. Quantbot Technologies LP bought a new position in TherapeuticsMD in the 3rd quarter worth approximately $189,000. Finally, Cetera Investment Advisers bought a new position in TherapeuticsMD in the 2nd quarter worth approximately $214,000. Hedge funds and other institutional investors own 73.69% of the company’s stock.

WARNING: “Zacks Investment Research Downgrades TherapeuticsMD (TXMD) to Sell” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2018/01/14/zacks-investment-research-downgrades-therapeuticsmd-txmd-to-sell.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Stock Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related stocks with our FREE daily email newsletter.